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Abstract
Introduction As asthma medications are frequently prescribed for children, knowledge of the safety of these drugs in the 
paediatric population is important. Although spontaneous reports cannot be used to prove causality of adverse events, they 
are important in the detection of safety signals.
Objective Our objective was to provide an overview of adverse drug events associated with asthma medications in children 
from a spontaneous reports database and to identify new signals.
Methods Spontaneous reports concerning asthma drugs were obtained from EudraVigilance, the European Medicine 
Agency’s database for suspected adverse drug reactions. For each drug–event combination, we calculated the proportional 
reporting ratio (PRR) in the study period 2011–2017. Signals in children (aged 0–17 years) were compared with signals in 
the whole population. Analyses were repeated for different age categories, by sex and by therapeutic area.
Results In total, 372,345 reports in children resulted in 385 different signals concerning asthma therapy. The largest group 
consisted of psychiatric events (65 signals). Only 30 signals were new, with seven, including herpes viral infections, associ-
ated with omalizumab. Stratification by age, sex and therapeutic area provided additional new signals, such as hypertrichoses 
with budesonide and encephalopathies with theophylline. Of all signals in children, 60 (16%) did not appear in the whole 
population.
Conclusions The majority of signals regarding asthma therapy in children were already known, but we also identified new 
signals. We showed that signals can be masked if age stratification is not conducted. Further exploration is needed to inves-
tigate the risk and causality of the newly found signals.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 4-019-00870 -x) contains 
supplementary material, which is available to authorized users.
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Key Points 
Most safety signals regarding asthma therapy in children 
are known, but we identified several new signals that 
need to be explored further.
Lack of stratification by age and sex may mask safety 
signals in children.
1 Introduction
Asthma drugs are one of the most frequently used drugs 
in children, with approximately 21% of children aged 
2–11 years using asthma medication [1, 2]. Since asthma is a 
chronic disease, this medication may be used for many years 
[3]. Like any drug, asthma medication may cause adverse 
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reactions. Randomized controlled trials (RCTs) are the gold 
standard to investigate the efficacy of drugs but are limited 
in size and follow-up and therefore can only detect events 
that occur frequently and may miss rare or long-term side 
effects. Children remain underrepresented in RCTs, even 
though attempts have been made to increase these numbers, 
including the Paediatric Regulation that came into force 
in the EU in 2007 [4–7]. Given the lack of data, medica-
tion—including asthma drugs—is often not authorised for 
use in children, leading to substantial off-label use [8]. This 
is concerning because the efficacy and safety profile of drugs 
might differ between children and adults [9]. The risk assess-
ment of drugs does not stop after market authorisation but 
should be monitored throughout the lifecycle of the drug 
[10]. Clearly, more child-specific safety and efficacy infor-
mation on asthma drugs is needed, something the European 
Medicines Agency (EMA) emphasises [11].
Spontaneous report databases are an important source 
of safety information, and in fact remain the most frequent 
source from which regulatory action is initiated [12]. They 
cover large source populations, including special popula-
tions such as children, and may have more power to detect 
rare signals than mining of electronic healthcare records 
[13–15]. The EMA defines an adverse drug reaction as “a 
response to a medicinal product which is noxious and unin-
tended” [16]. Spontaneous reports only contain information 
on the event and the drug of interest, not on the non-exposed 
events or exposure without events, so cannot be used to 
measure incidence rates. However, signal detection based 
on disproportionality analyses is still possible [15, 17, 18]. 
Since the risk of adverse events can be age specific, strati-
fication of these analyses is recommended [19]. A previous 
study using EudraVigilance, the European database for sus-
pected adverse reactions, characterised spontaneous reports 
of asthma drugs in children over the study period 2007–2011 
[20]. The authors could not identify new signals in relation 
to asthma drugs, potentially because of low numbers. In this 
study, we aimed to investigate the safety of asthma drugs in 
children in EudraVigilance in the period 2011–2017. The 
objective of this study was to provide an overview of safety 
signals associated with asthma drugs in children and to iden-
tify new signals in the EudraVigilance database.
2  Methods
2.1  Database
We used the EudraVigilance database, which is developed 
and maintained by the EMA to collect reports of suspected 
adverse reactions. It contains adverse events reported in rela-
tion to any drug authorised or being studied in the Euro-
pean economic area. EudraVigilance contains spontaneous 
reports from healthcare professionals, patients and market-
ing authorisation holders and clinical trial safety data dat-
ing back to 1995. The number of new reports in this data-
base increases each year, with 1,238,178 reports of adverse 
events collected in 2016 [21]. Events are coded using the 
Medical Dictionary for Regulatory Activities (MedDRA). 
For this study, information on the frequency of MedDRA 
(version 20.1) ‘high-level terms’ in spontaneous reports 
regarding asthma drugs was obtained. These terms are 
grouped by ‘system organ classes’ (SOCs), for example, 
by aetiology (‘infections and infestations’) or manifestation 
site (‘respiratory, thoracic and mediastinal disorders’) [22]. 
Drugs are coded by anatomical therapeutic chemical (ATC) 
classification.
2.2  Data Selection
All spontaneous reports submitted to EudraVigilance 
between 1 January 2011 and 1 January 2017 and concern-
ing 24 asthma drugs were analysed. Reports concerning sus-
pect or interacting single drugs or fixed-dose combinations 
from the following drug classes were included: β2-adrenergic 
receptor agonists, inhaled corticosteroids (ICS), muscarinic 
receptor antagonist, chromones, xanthines, leukotriene 
receptor antagonists (LTRAs) and anti-immunoglobulin 
E (IgE) drugs (Table 1). Counts of spontaneous reports 
were provided for the whole paediatric group, by sex, by 
age category (0–2, 3–11 and 12–17 years) and for adults. 
Reports that did not include the patient’s age were excluded. 
To calculate the measure of disproportionality, the back-
ground frequencies of adverse events for all drugs were also 
included in the data files. The free text narrative from the 
reports was not available because of data protection regula-
tions. The retrieved data were at the group level only and 
included non-identifiable patient data, so no ethics review 
board approval was required.
2.3  Signal Detection
As one report may contain multiple drugs and/or multiple 
adverse events, we defined the combination of one drug and 
one event as drug–event combinations (DECs). To identify 
signals, we calculated the disproportionality in reporting 
using the proportional reporting ratio (PRR), defined as the 
proportion of the event of interest for a specific drug, with 
the comparator being the proportion of the event of interest 
for all other drugs from the database (other asthma and non-
asthma drugs) [23]. The PRR was calculated only if a DEC 
was reported at least five times. We also calculated 95% 
confidence intervals (CIs), and the criterion for a signal was 
a lower bound higher than one (PRR025 > 1) [19, 24–26]. 
We first calculated the PRR in reports concerning children 
only, then in the whole dataset including children and adults 
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to examine masking of safety signals if stratification for 
children had not been done. We also repeated the analyses 
of paediatric reports while stratifying for age and sex [17]. 
Finally, we calculated another measurement of dispropor-
tionality—the PRR by therapeutic area (PRR-TA)—for pae-
diatric reports. For this calculation, only reports related to 
asthma drugs for other events were used as the comparator. 
The PRR-TA has been proposed in the literature as a method 
to eliminate false signals due to confounding by indication 
[27].
2.4  Definition of New Signals
To identify already known signals, we searched the safety 
information as documented in the summary of product char-
acteristics (SmPC). If the event was not listed in the SmPC, 
we also searched UpToDate and Martindale [28]. UpToDate 
is a widely used point-of-care clinical tool to support deci-
sion making that includes summaries of the current available 
evidence on medication, including possible adverse events 
[29–31]. Martindale is an online drug database published 
by the Pharmaceutical Press and is updated every 3 months 
[32]. If an adverse event was not mentioned by any of these 
sources, we considered the signal on this adverse event to 
be a new signal.
3  Results
From January 2011 to January 2017, a total of 372,345 spon-
taneous reports on adverse events in children and 3,182,083 
in adults were reported to EudraVigilance. From these 
reports, we identified 21,264 asthma medication-related 
DECs in children and 172,035 in adults for the same drugs. 
The asthma drug most often included in reports in children 
was montelukast (2210 reports), followed by inhaled salbu-
tamol (947) and anti-IgE (omalizumab, 690) (Table 1). We 
identified 3697 unique DECs, 385 of which met the criteria 
of a safety signal in children. All safety signals and cor-
responding SOCs are listed in the Electronic Supplemen-
tary Material (ESM) 1. Signals were mainly related to the 
SOCs ‘psychiatric disorders’ (n = 65), ‘respiratory, thoracic 
and mediastinal disorders’ (n = 56) and ‘nervous system 
disorders’ (n = 29) (Fig. 1). Signals also often related to 
Table 1  Number of reports per 
drug in children
ATC anatomical therapeutic chemical, ICS inhaled  corticosteroids, LABA long-acting β-agonist, LAMA 
long-acting muscarinic antagonist, LTRA leukotriene receptor antagonist, SABA short-acting β-agonist, 
SAMA short-acting muscarinic antagonist
ATC code Drug name Administration Drug class Reports (N)
R03DC03 Montelukast Oral LTRA 2210
R03AC02 Salbutamol Inhaled SABA 947
R03DX05 Omalizumab Subcutaneous Monoclonal antibody 690
R03CC02 Salbutamol, systemic Oral, intravenous SABA 676
R03BA02 Budesonide Inhaled ICS 584
R03AK06 Salmeterol + fluticasone Inhaled LABA + ICS 565
R03BA05 Fluticasone Inhaled ICS 391
R03BA01 Beclomethasone Inhaled ICS 169
R03AK07 Formoterol + budesonide Inhaled LABA + ICS 161
R03DA04 Theophylline Oral, intravenous Xanthine 98
R03CC03 Terbutaline, systemic Oral, intravenous SABA 87
R03BB01 Ipratropium bromide Inhaled SAMA 85
R03AC13 Formoterol Inhaled LABA 80
R03AC03 Terbutaline Inhaled SABA 73
R03BA08 Ciclesonide Inhaled ICS 36
R03BC01 Cromoglicic acid Inhaled Chromones 34
R03AC12 Salmeterol Inhaled LABA 32
R03BA07 Mometasone Inhaled ICS 31
R03DC01 Zafirlukast Oral LTRA 29
R03AL01 Fenoterol and ipratropium bromide Inhaled LABA + SAMA 24
R03AL02 Salbutamol and ipratropium bromide Inhaled SABA + SAMA 21
R03AK10 Vilanterol and fluticasone furoate Inhaled LABA + ICS 16
R03BB04 Tiotropium bromide Inhaled LAMA 9
R03AK11 Formoterol and fluticasone Inhaled LABA + ICS 3
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‘Injury, poisoning and procedural complications’ (n = 49), 
which included for example ‘off-label uses’ and ‘accidental 
exposure to product’. We identified 31 signals of psychiatric 
adverse events in combination with montelukast, which also 
included the five most frequently reported DECs (Table 2). 
The highest PRR in children was for the association between 
montelukast use and ‘vasculitides’ (PRR 90.7; 95% CI 
46.3–177.9; 13 reports), followed by fluticasone and ‘adre-
nal cortical hypofunctions’ (PRR 59.5; 95% CI 39.1–90.4; 
22 reports) (Table 3). All ten signals with the highest PRR 
were already known.
3.1  New Signals
Most of the 385 signals in children were already known and 
thus described in the SmPC, UpToDate and/or Martindale; 
only 30 were classified as new. New signals most often con-
cerned omalizumab, with seven new signals, followed by 
the fixed combination of salmeterol and fluticasone (six new 
signals) and montelukast (five new signals) (Table 4). See 
the ESM for a table presenting all signals not described in 
the SmPC but mentioned in UpToDate and/or Martindale.
3.2  Proportional Reporting Ratio by Therapeutic 
Area
The results of the PRR-TA differed from those of the overall 
PRR. Of all the signals, 126 disappeared when calculating 
the PRR-TA. This difference was most pronounced for ‘res-
piratory, thoracic and mediastinal’ disorders, as half of these 
signals disappeared when calculating the PRR-TA. On the 
other hand, the overall PRR of 38 DECs did not meet the 
definition of a safety signal, whereas the PRR-TA did show a 
signal. Three of these safety signals were new: omalizumab 
with ‘bacterial infections NEC [not elsewhere classified]’ 
and both omalizumab and budesonide with ‘herpes viral 
infections’ (Table 5).
3.3  Children Versus All Ages
Of the 385 signals in children, 60 (16%) DECs no longer 
met the criteria of a signal when calculating the PRR in the 
whole dataset including all ages (both children and adults). 
All signals in children concerning the SOC ‘respiratory, tho-
racic and mediastinal disorders’ remained in the dataset that 
included children and adults together. In contrast, only 35 of 
the 50 signals in children concerning ‘psychiatric disorders’ 
remained in the whole dataset (Fig. 1).
3.4  Stratification by Age
Of all asthma medication-related DECs in children, 4429 
(21%) pertained to children aged 0–2 years, 11,319 (53%) 
to children aged 3–11 years and 5516 (26%) to children 
aged 12–17 years. Upon stratification by age, 42 additional 
safety signals appeared: 16 of these were in the age cat-
egory 0–2 years, 14 in the category 3–11 years and 12 in 
the category 12–17 years. These safety signals concerned 
‘pregnancy, puerperium and perinatal disorders’ for events 
referring to in utero exposure and ‘general disorders and 
administration site conditions’, ‘gastrointestinal disorders’, 
‘psychiatric disorders’ and ‘nervous system disorders’. Six 
(14%) of the signals that only appeared upon age stratifica-
tion were classified as new (Table 6).
Fig. 1  Signals in children categorized as to whether it remains a signal in the whole dataset (children and adults)
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Table 2  Drug–event 
combinations of montelukast 
and psychiatric events
CI confidence interval, HLT high-level term, NEC not elsewhere classified, PRR proportional reporting 
ratio
Reaction HLT Reports (N) PRR (95% CI)
Behaviour and socialisation disturbances 328 16.0 (14.4–17.8)
Parasomnias 252 49.5 (43.3–56.6)
Anxiety symptoms 249 6.4 (5.7–7.2)
Emotional and mood disturbances NEC 247 6.9 (6.1–7.7)
Suicidal and self-injurious behaviour 219 7.1 (6.3–8.1)
Abnormal behaviour NEC 211 9.7 (8.5–11.1)
Disturbances in initiating and maintaining sleep 163 10.4 (8.9–12.1)
Depressive disorders 142 10.2 (8.6–12.0)
Fear symptoms and phobic disorders (including social phobia) 72 27.5 (21.5–35.1)
Mood alterations with depressive symptoms 67 8.0 (6.3–10.2)
Sleep disorders NEC 66 7.0 (5.5–9.0)
Increased physical activity levels 63 3.4 (2.7–4.3)
Speech articulation and rhythm disturbances 61 6.3 (4.9–8.1)
Fluctuating mood symptoms 59 20.6 (15.8–26.9)
Attention deficit and disruptive behaviour disorders 33 14.8 (10.4–21.0)
Tic disorders 32 8.1 (5.7–11.5)
Mood disorders NEC 32 2.5 (1.7–3.5)
Obsessive-compulsive disorders and symptoms 32 14.8 (10.4–21.3)
Panic attacks and disorders 30 10.7 (7.4–15.5)
Thinking disturbances 28 15.4 (10.5–22.7)
Confusion and disorientation 25 2.0 (1.3–2.9)
Sleep disturbances NEC 22 4.6 (3.0–7.0)
Affect alterations NEC 21 9.3 (6.0–14.4)
Personality disorders NEC 20 23.3 (14.6–37.1)
Psychotic disorder NEC 18 3.2 (2.0–5.1)
Educational issues 18 26.0 (15.8–42.6)
Psychiatric elimination disorders 17 12.7 (7.8–20.8)
Criminal activity 12 12.4 (6.9–22.3)
Anxiety disorders NEC 10 14.8 (7.8–28.3)
Stereotypies and automatisms 9 4.4 (2.3–8.5)
Impulse control disorders 7 6.1 (2.9–12.9)
Table 3  Top ten strongest 
signals
CI confidence interval, HLT high-level term
Name Reaction HLT Reports (N) PRR (95% CI)
Montelukast Parasomnias 252 49.5 (43.3–56.6)
Salmeterol + fluticasone Adrenal cortical hypofunctions 30 57.4 (39.9–82.6)
Fluticasone Adrenal cortical hypofunctions 22 59.5 (39.1–90.4)
Budesonide Adrenal cortical hypofunctions 22 39.8 (26.1–60.7)
Budesonide Cataract conditions 17 58.5 (35.8–95.5)
Montelukast Vasculitides 13 90.7 (46.3–177.9)
Salbutamol, inhaled Thermal burns 13 35.4 (20.1–62.2)
Salmeterol + fluticasone Glaucomas (excluding congenital) 9 34.0 (17.5–66.2)
Fluticasone Cataract conditions 7 34.1(16.2–72.1)
Fluticasone Dental and periodontal infections and 
inflammations
5 46.2 (18.9–112.7)
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3.5  Stratification by Sex
The sex of the patient was known in 20,726 DECs (98%), 
with 11,926 (56%) DECs concerning boys and 8800 (41%) 
concerning girls. Upon sex stratification, 289 (77%) signals 
remained. On the other hand, 30 DECs additionally met 
the definition of a safety signal, four of which (two each in 
males/females) were classified as new (Table 7). More sig-
nals appeared in boys only (97 signals) than in girls only (35 
Table 4  All new signals by drug
CI confidence interval, HLT high-level term, NEC not elsewhere classified, PRR-TA proportional reporting ratio by therapeutic area, SOC system 
organ class
a PRR-TA could not be calculated as the event was not reported in combination with other asthma drugs
Reaction HLT Reports PRR (95% CI) PRR-TA (95% CI) SOC
Budesonide
 Leukopenias NEC 8 3.5 (1.7–6.9) 14.8 (5.1–42.4) Immune system disorders
 Hypertrichoses 5 17.8 (7.3–43.1) 11.1 (3.2–38.1) Skin and subcutaneous disorders
Fluticasone
 Dyskinesias and movement disorders NEC 13 2.3 (1.3–3.9) 1.3 (0.7–2.2) Nervous system disorders
 Mental impairment (excluding dementia and 
memory loss)
5 2.8 (1.2–6.6) 1.3 (0.5–3.2) Nervous system disorders
 Hypoglycaemic conditions NEC 5 2.9 (1.2–7.1) 2.7 (1.0–6.8) Metabolism and nutrition disorders
Ipratropium bromide
 Tremor (excluding congenital) 6 6.6 (3.1–14.3) 2.2 (1.0–4.7) Nervous system disorders
Montelukast
 Paraesthesias and dysaesthesias 43 2.0 (1.5–2.7) 1.5 (1.0–2.2) Nervous system disorders
 Skin injuries NEC 15 2.2 (1.3–3.7) 1.8 (0.9–3.6) Skin and subcutaneous disorders
 Eyelid movement disorders 10 3.9 (2.1–7.2) 5.5 (1.7–17.4) Eye disorders
 Lacrimation disorders 6 2.4 (1.1–5.3) 1.1 (0.4–2.9) Eye disorders
 Panniculitides 5 4.8 (2.0–11.8) a Skin and subcutaneous disorders
Omalizumab
 Neurological signs and symptoms NEC 38 1.6 (1.2–2.2) 2.7 (1.9–3.8) Nervous system disorders
 Feelings and sensations NEC 27 2.5 (1.7–3.6) 2.5 (1.6–3.8) Nervous system disorders
 Visual disorders NEC 11 2.0 (1.1–3.6) 2.0 (1.1–3.9) Eye disorders
 Speech and language abnormalities 9 2.2 (1.1–4.1) 2.1 (1.0–4.3) Nervous system disorders
 Exfoliative conditions 6 3.1 (1.4–7.0) 3.5 (1.4–8.8) Skin and subcutaneous disorders
 Sensory abnormalities NEC 5 2.7 (1.1–6.5) 2.4 (0.9–6.5) Nervous system disorders
 Oral soft tissue pain and paraesthesia 5 6.7 (2.8–16.3) 4.6 (1.6–13.5) Gastrointestinal disorders
Salbutamol, inhaled
 Non-site specific vascular disorders NEC 9 3.9 (2.0–7.5) 4.8 (2.0–11.4) Vascular disorders
 Psychotic disorder NEC 8 3.3 (1.6–6.6) 1.2 (0.6–2.5) Psychiatric disorders
Salbutamol, systemic
 Psychotic disorder NEC 8 4.6 (2.3–9.2) 1.7 (0.8–3.6) Psychiatric disorders
 Non-site specific vascular disorders NEC 6 3.6 (1.6–8.1) 3.8 (1.5–9.7) Vascular disorders
Salmeterol + fluticasone
 Visual disorders NEC 10 2.2 (1.2–4.2) 2.3 (1.2–4.4) Eye disorders
 Increased intracranial pressure disorders 9 4.3 (2.2–8.2) 4.1 (1.9–8.8) Nervous system disorders
 Confusion and disorientation 7 2.2 (1.0–4.5) 1.7 (0.8–3.8) Psychiatric disorders
 Hypoglycaemic conditions NEC 7 2.9(1.4–6.0) 2.7 (1.2–6.1) Metabolism and nutrition disorders
 Tic disorders 6 5.7 (2.6–12.7) 2.1 (0.9–5.0) Psychiatric disorders
 Memory loss (excluding dementia) 5 3.1 (1.3–7.4) 2.1 (0.8–5.5) Nervous system disorders
Theophylline
 Encephalopathies NEC 6 9.8 (4.5–21.4) 212.9 (43.5–1041.5) Nervous system disorders
 Abnormal behaviour NEC 5 4.9 (2.1–11.6) 1.2 (0.5–2.9) Psychiatric disorders
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signals). Signals more often appeared in boys than in girls 
for ‘psychiatric disorders’, ‘musculoskeletal and connective 
tissue disorders’ and ‘eye disorders’, whereas they appeared 
more often in girls for ‘cardiac disorders’ (Fig. 2).
4  Discussion
In this study, we investigated spontaneous reports of adverse 
events related to asthma drugs in children. We were able to 
include fivefold more reports than a previous analysis of 
EudraVigilance data from 2007 to 2011 [20]. We observed 
that spontaneous reports for montelukast were the most fre-
quent, followed by reports for salbutamol, omalizumab and 
budesonide. Although 92% of the statistical signals were 
already known, we observed 30 new signals, especially for 
omalizumab. Calculation of the PRR by therapeutic area, age 
and sex revealed additional new signals, pointing to mask-
ing due to confounding by indication or effect modification.
Safety signals of asthma drugs were mainly related to 
psychiatric disorders, especially in combination with the 
use of montelukast. This is in line with a recent review that 
concluded that LTRAs are frequently associated with neu-
ropsychiatric adverse events [6]. Awareness of the poten-
tial for psychiatric adverse events when initiating treatment 
with asthma drugs is important so that stopping treatment 
may be considered when the first symptoms of psychiatric 
events are observed. The second largest group of safety sig-
nals, ‘respiratory, thoracic and mediastinal disorders’, is of 
course prone to confounding by indication. This is further 
supported by our observation that half of the signals from 
this group disappeared when we calculated the PRR-TA.
Some observed new signals were already reported in the 
literature but not included in the SmPC, Martindale and 
UpToDate. For example, a study of spontaneous reports 
from Lareb, The Netherlands Pharmacovigilance Cen-
tre [33] associated hypertrichosis, both statistically and 
through causality assessment, with ICS, and cases of acute 
Table 5  New signals unmasked 
by PRR-TA
CI confidence interval, HLT high-level term, NEC not elsewhere classified, PRR-TA proportional reporting 
ratio by therapeutic area
Drug Reaction HLT Reports (N) PRR (95% CI) PRR-TA (95% CI)
Budesonide Herpes viral infections 9 1.0 (0.5–1.9) 7.7 (3.3–17.9)
Omalizumab Herpes viral infections 8 0.8 (0.4–1.5) 5.3 (2.2–12.5)
Omalizumab Bacterial infections NEC 6 0.8 (0.4–1.8) 13.8 (3.9–48.9)
Table 6  New signals unmasked by stratification for age
CI confidence interval, HLT high-level term, NEC not elsewhere classified, PRR proportional reporting ratio
Drug Reaction HLT Overall PRR (95% CI) Age group, years Reports in 
age group
PRR in age group (95% CI)
Salbutamol, inhaled Perception disturbances 1.5 (0.9–2.6) 0–2 6 14.8 (6.6–33.0)
Salbutamol, inhaled Cardiac septal defects congenital 2.0 (0.8–4.7) 0–2 5 2.8 (1.2–6.6)
Budesonide Neutropenias 1.8 (1.0–3.3) 0–2 5 3.6 (1.5–8.5)
Theophylline Febrile disorders 1.1 (0.7–1.7) 3–11 13 2.3 (1.4–3.6)
Montelukast Diabetes mellitus (including sub-
types)
1.6 (0.9–3.0) 3–11 11 2.3 (1.3–4.2)
Omalizumab Cardiac signs and symptoms NEC 1.2 (0.7–2.1) 3–11 5 2.8 (1.2–6.6)
Montelukast Gastrointestinal atonic and hypomo-
tility disorders NEC
1.2 (0.7–2.1) 12–17 5 2.8 (1.2–6.6)
Table 7  New signals unmasked by stratification for sex
CI confidence interval, HLT high-level term, NEC not elsewhere classified, PRR proportional reporting ratio
Drug Reaction HLT Overall PRR (95% CI) Sex Reports PRR-sex (95% CI)
Fluticasone Appetite disorders 1.5 (0.9–2.8) Female 7 2.5 (1.2–5.1)
Montelukast Alopecias 1.5 (0.8–2.8) Male 6 2.9 (1.3–6.5)
Montelukast Flatulence, bloating and distension 1.3 (0.7–2.5) Female 6 2.5 (1.1–5.5)
Omalizumab Lid, lash and lacrimal infections, irrita-
tions and inflammations
1.9 (0.8–4.5) Male 5 3.5 (1.5–8.5)
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encephalopathies have been described with theophylline 
use. Although seizures are already listed as adverse reac-
tions in the SmPC of theophylline, multiple cases of post-
ictal coma lasting > 24 h have been described, regarding it 
as acute encephalopathy instead of a mere seizure [34]. We 
also found ‘herpes viral infections’ as a new signal associ-
ated with omalizumab. An increase in oral herpes in patients 
using omalizumab, without reaching statistical significance, 
has been mentioned in the literature [35]. One case of herpes 
labialis has been described in the literature, with the timing 
of herpes relapses directly related to omalizumab treatment 
[36]. Further studies should be conducted to confirm these 
new safety signals and investigate possible mechanisms.
Omalizumab, a monoclonal anti-IgE antibody, has been 
authorized in Europe since 2005. It is prescribed by spe-
cialist physicians to patients with asthma and IgE-mediated 
allergy that is difficult to control. Our results indicated new 
safety signals for omalizumab, including herpes viral infec-
tions, bacterial infections and visual disorders. The indica-
tion of use—namely, severe allergic asthma—implies that 
these patients were treated not only with omalizumab but 
also with other asthma drugs, especially high-dose ICS and 
systemic corticosteroids, both of which have immunosup-
pressive effects. Omalizumab is a systemic drug adminis-
tered via intramuscular injection instead of inhaler therapy, 
which could also explain the relatively high number of 
reports.
We showed that many safety signals in children did not 
meet the criteria of a signal when calculating the PRR in 
the whole dataset that included adults. This means that such 
signals would have been missed had we not examined spon-
taneous reports in children separately. We also observed the 
importance of stratification for age within the paediatric 
group. Studies have demonstrated that stratification for age 
may unmask signals but adjustment for age does not improve 
the analyses [37, 38]. This emphasises the importance of 
actively monitoring the safety of drugs in children. When 
stratifying by sex, most signals remained. The prevalence 
of asthma, and thus the use of asthma drugs, is higher in 
boys than in girls. This may explain why more signals were 
reported for boys than for girls, as at least five reports are 
required for a signal [39].
The strength of our study lies in our use of one of the 
largest databases of spontaneous reports and data from 
many different countries, covering a heterogeneous paedi-
atric population. This provided us with the opportunity to 
study the safety of a drug in real life and to report on signals 
of a relatively new drug, omalizumab. It also allowed us 
to stratify for age and sex. Spontaneous reports remain the 
most important source of detecting (new) safety signals, but 
the use and interpretation of these data has some limitations 
[14]. First, underreporting is likely in spontaneous report 
databases, and the adverse events that are reported are only 
the tip of the iceberg [40]. Another challenge of this type of 
study is that the MedDRA terms do not always match exactly 
the adverse reactions as mentioned in the SmPC and litera-
ture. This makes it difficult to interpret whether a signal is an 
already known adverse reaction. Reports might consist of a 
combination of multiple events and multiple drugs, and we 
were unable to deduct which was the culprit drug from these 
data, even though we only included those that were reported 
as suspected or interacting. Additional information from 
the report, such as the complete narrative, might have given 
more insight; unfortunately, data protection regulations 
Fig. 2  Signals after stratification by sex categorized as a signal in boys only, girls only or both sexes
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meant these were unavailable. Also, some events were not 
reported frequently. This resulted in wide CIs, which require 
careful interpretation of the PRR. Finally, although we did 
have different combinations of medication and drugs, we did 
not have the number of reports containing a certain event 
combined with at least one type of asthma medication. This 
may have led to an underestimation of the true PRR-TA as 
the denominator was the number of combinations between 
the event and all asthma drugs.
For pharmacovigilance, it is paramount that any new sus-
pected adverse drug reactions are reported immediately and 
include important details such as age and sex. This reporting 
is facilitated via online submission through the EudraVigi-
lance website [41]. EudraVigilance also provides health-
care professionals with a graphical overview of the type of 
reported adverse drug reactions (by age, sex, type of reporter 
and outcome) of all centrally authorised drugs.
5  Conclusion
We characterized spontaneous reports of asthma drugs in 
children. We again showed the importance of investigating 
adverse events in children separately from adults and in dif-
ferent age and sex strata. We identified new signals that need 
to be further followed-up to investigate the true associations 
and causality.
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